Oruka Therapeutics, Inc. (ORKA)
Develops antibody drugs to treat psoriasis and immune system diseases.
$90.45+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+565.1%
The outlook
ORKA is trading near the top of its 52-week range, well above both its 50- and 200-day averages. Analysts collectively rate it a Strong Buy, with the average price target sitting about 64% above the current price. The stock shows a bullish technical and fundamental setup based on current market data.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 12 analysts
Price trendAbove its 50- & 200-day averages
52-week range91% of the way from its 52-week low to high
Price targetAvg target +64% vs current price
Analyst price target
~12-month · 12 analysts$148.17average target+63.8% vs now
Now $90.45
Low $102.00High $200.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$5.46B
52-wk high
$97.78
52-wk low
$12.84
50-day avg
$75.34
200-day avg
$47.64
Trailing P/E
—